Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare.
Rituximab improves survival in follicular lymphoma (FL), but is considerably more expensive than conventional chemotherapy. We estimated the total direct medical costs, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for FL, based on a single source of data...
主要な著者: | Griffiths, R, Gleeson, M, Mikhael, J, Danese, MD |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
2012
|
類似資料
-
Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma
著者:: Griffiths, R, 等
出版事項: (2012) -
Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma.
著者:: Griffiths, R, 等
出版事項: (2012) -
Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma.
著者:: Griffiths, R, 等
出版事項: (2011) -
Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-Medicare.
著者:: Griffiths, R, 等
出版事項: (2012) -
Survival in elderly follicular lymphoma patients who receive frontline chemo-immunotherapy.
著者:: Griffiths, R, 等
出版事項: (2010)